Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Peristeri – page 14

1 033 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Peristeri at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Peristeri

Open in trial search

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:AZD5148
  • Sponsor:AstraZeneca AB

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

A study to evaluate the safety and effects of inebilizumab in children and adolescents with immunoglobulin G4-related disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Still's disease+1

Recruiting

A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Phase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Etelcalcetide
  • Sponsor:Amgen Inc.

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:AZD4144
  • Sponsor:AstraZeneca AB

Study comparing firmonertinib with osimertinib or afatinib for patients with advanced lung cancer with uncommon EGFR mutations

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Arrivent Biopharma Inc.

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Peristeri

What the registry says about research in the country

01 Cardiovascular Diseases

In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.

  • Composite cardiovascular outcome assessment
  • Weekly dosing strategy
  • Integration with standard of care
  • Focus on heart‑failure subtypes

Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.

02 Nutritional and Metabolic Diseases

Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.

  • Weight‑loss non‑inferiority testing
  • Superiority versus placebo evaluation
  • Adjunct lifestyle intervention
  • Targeting overweight and obesity

The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.